Overview
Aditya Halthore, MD, serves as Assistant Professor in the Department of Radiation Oncology and Molecular Radiation Sciences and Director of Safety and Quality at the Johns Hopkins University School of Medicine. Listen to Dr. Halthore's On Target podcast episode to learn more about his work. Dr. Halthore is an expert in proton therapy and specializes in genitourinary and thoracic cancers. His specific interests include prostate, bladder, lung, esophageal, and thymic cancers, and he is committed to developing personalized treatment strategies for every patient. Dr. Halthore was previously recognized as a Howard Hughes Medical Institute (HHMI)/National Institutes of Health (NIH) Scholar and his research interests include grant funded clinical trials focused on the novel utilization of radiation and imaging techniques, such as spatial fractionation (proton GRID) therapy for the treatment of bulky cancers. He is also involved in using dual-energy CT and functional MRI studies that aim to improve functional radiation planning and the assessment of radiation-induced changes. As an educator, Dr. Halthore serves as Course Director for the Johns Hopkins Proton Therapy Certificate Program. He actively participates in student, resident, and fellow lectureship and mentorship across the Johns Hopkins health system. Dr. Halthore participates in several national-level initiatives including as a member of the American Society of Therapeutic Radiation Oncology (ASTRO) Guidelines Subcommittee and as a board member and ASTRO liaison to the Medical Dosimetry Certification Board (MDCB).
Dr. Halthore is rated as an Advanced provider by MediFind in the treatment of Marginal Zone Lymphoma (MZL). His top areas of expertise are Prostate Cancer, Small Cell Lung Cancer (SCLC), Marginal Zone Lymphoma (MZL), and Familial Prostate Cancer.
His clinical research consists of co-authoring 22 peer reviewed articles. MediFind looks at clinical research from the past 15 years.
Insurance
Accepted insurance can change. Please verify directly with the provider.
Accepted insurance plans:
- EPO
- HMO
- POS
- PPO
- EPO
- HMO
- POS
- PPO
- HMO
- POS
- PPO
- EPO
- HMO
- PPO
- INSURANCE PLAN
- MEDICARE PDP
- PPO
- HMO
- POS
- PPO
- HMO
- INDEMNITY
- POS
- PPO
- HMO
- MANAGED MEDICAID PLAN
- MEDICARE MAPD
- MEDICARE-MEDICAID PLAN
- OTHER MANAGED MEDICAID
- EPO
- HMO
- POS
- PPO
- EPO
- HMO
- INSURANCE PLAN
- MANAGED MEDICAID PLAN
- MEDICARE MAPD
- MEDICARE PDP
- MEDICARE SNP
- MEDICARE-MEDICAID PLAN
- OTHER MEDICARE
- OTHER MEDICARE PART D
Locations
5255 Loughboro Road Northwest, Washington, DC 20016
300 Mason Lord Drive, Kimmel Cancer Center, Baltimore, MD 21224
5255 Loughboro Road Northwest, Washington, DC 20016
Clinical Research
Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.
Sibley Memorial Hospital
Marie Kate Gurka, M.D., is a radiation oncologist in the Department of Radiation Oncology at the Johns Hopkins Kimmel Cancer Center at Sibley Memorial Hospital and a clinical associate in the Department of Radiation Oncology at The Johns Hopkins Hospital. Dr. Gurka has expertise in radiation treatment for breast cancer and gynecologic cancers. Dr. Gurka earned her medical degree from Virginia Commonwealth University and completed a residency in radiation oncology at Georgetown University Hospital. She previously served as an instructor in the Department of Radiation Oncology at University of Louisville and has conducted both clinical and basic science research. Her work has been recognized by the American Society for Radiation Oncology (ASTRO), and the American Society of Clinical Oncology (ASCO), and it has been cited in various lectures, research articles, and textbooks. Washingtonian Magazine and Bethesda Magazine have repeatedly named Dr. Gurka a Top Doctor. Selected Publications Oermann EK, Bhandari R, Chen V, Lebec G, Gurka M, Lei S, Chen L, Suy, S, Azumi N, Berkowitz F, Kalhorn C, McGrail K, Collins BT, Jean W, Collins SP. Five Fraction Image-Guided Radiosurgery for Primary and Recurrent Meningiomas. Frontiers in Radiation Oncology. 2013; 3: 213. Gurka MK, Collins SP, Slack R, Tse G, Charabaty A, Ley L, Berzcel L, Lei S, Suy S, Haddad N, Jha R, Johnson CD, Jackson P, Marshall JL, Pishvaian MJ. Stereotactic Body Radiation Therapy with Concurrent Full-Dose Gemcitabine for Locally Advanced Pancreatic Cancer: A Pilot Trial Demonstrating Safety. Radiation Oncology. 2013; 8: 44. Gurka MK, Kim C , Carroll J, Charabaty A, Haddad M, Jackson P, Collins SP, Marshall J, Pishvaian MK, Unger KR. Stereotactic Body Radiation Therapy (SBRT) combined with chemotherapy for unresected pancreatic adenocarcinoma. American Journal of Clinical Oncology. 2014; 152-157. Gurka MK, Horne ZD, Ju A, Chen L, Lei S, Batipps GP, Kowalczyk K, Bandi G, Pahira J, McGeagh KG, Collins BT, Krishnan P, Suy S, Dritschilo A, Lynch JH, Collins SP. Hematuria Following Stereotactic Body Radiation Therapy (SBRT) for Clinically Localized Prostate Cancer. Radiation Oncology. 2015; 10:44. Gurka MK, Pender D, Chuong P, Fouts B, Sebelov A, McNally M, Mezera M, Woo SY, McNally R. Identification of pancreatic tumors in vivo with ligand-targeted, pH responsive mesoporous silica nanoparticles by multispectral optoacoustic tomography. Journal of Controlled Release. 2016; 231:60-67. Dr. Gurka is rated as an Advanced provider by MediFind in the treatment of Marginal Zone Lymphoma (MZL). Her top areas of expertise are Breast Cancer, Intraductal Papilloma, Gliomatosis Cerebri, and Marginal Zone Lymphoma (MZL).
Virginia Cancer Specialists, P.C.
Harold Agbahiwe is a Radiation Oncologist in Fairfax, Virginia. Dr. Agbahiwe is rated as an Advanced provider by MediFind in the treatment of Marginal Zone Lymphoma (MZL). His top areas of expertise are Pleuropulmonary Blastoma, Bone Tumor, Metastatic Brain Tumor, and Primitive Neuroectodermal Tumor (PNET). Dr. Agbahiwe is currently accepting new patients.
Radiation Oncology Associates PC
Tobias Chapman is a Radiation Oncologist in Falls Church, Virginia. Dr. Chapman is rated as an Advanced provider by MediFind in the treatment of Marginal Zone Lymphoma (MZL). His top areas of expertise are Familial Prostate Cancer, Prostate Cancer, HER-2 Positive Breast Cancer, and Metastatic Brain Tumor. Dr. Chapman is currently accepting new patients.
Areas of Expertise
MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.
Learn more about MediFind’s expert tiers
- Distinguished
- Prostate CancerDr. Halthore isDistinguished. Learn about Prostate Cancer.
- Advanced
- ALK-Positive Non-Small Cell Lung Cancer
- Breast CancerDr. Halthore isAdvanced. Learn about Breast Cancer.
- Familial Prostate CancerDr. Halthore isAdvanced. Learn about Familial Prostate Cancer.
- Lung AdenocarcinomaDr. Halthore isAdvanced. Learn about Lung Adenocarcinoma.
- Marginal Zone Lymphoma (MZL)Dr. Halthore isAdvanced. Learn about Marginal Zone Lymphoma (MZL).
- Pleuropulmonary BlastomaDr. Halthore isAdvanced. Learn about Pleuropulmonary Blastoma.
- Experienced
- Adult Soft Tissue SarcomaDr. Halthore isExperienced. Learn about Adult Soft Tissue Sarcoma.
- EGFR Positive Lung CancerDr. Halthore isExperienced. Learn about EGFR Positive Lung Cancer.
- Fibrodysplasia Ossificans ProgressivaDr. Halthore isExperienced. Learn about Fibrodysplasia Ossificans Progressiva.
- Large-Cell Lung CarcinomaDr. Halthore isExperienced. Learn about Large-Cell Lung Carcinoma.
- Laryngeal CancerDr. Halthore isExperienced. Learn about Laryngeal Cancer.
- Lung CancerDr. Halthore isExperienced. Learn about Lung Cancer.